Page 2 - Junshi Bioscience News Today

SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited ("Dr.

SHANGHAI, China, April 27, 2023 -- Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of... | April 27, 2023

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma

Perioperative toripalimab plus chemotherapy significantly improved EFS and reduced risk of disease recurrence, progression events or death by 60% among resectable stage III NSCLC patients, compared to

SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading...

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint

SHANGHAI, China, March 31, 2023 -- Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of... | March 31, 2023

-- The two parties will collaborate to develop and commercialize toripalimab in 9 Southeast Asian countries through a joint venture company, Excellmab --...

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia